The private sector has little appetite for manufacturing small-volume, niche vaccines for pandemic viruses. That’s why any primary manufacturing facility for vaccines like COVID-19 need to be federally owned and operated.
Organizations: | GlaxoSmithKline, Health Canada, Life Sciences BC, Merck, Novateur Ventures, Pfizer, Sanofi, Vaccine Research Institute, and Vaccines Manufacturing and Innovation Centre |
People: | Ali Ardakani |
Topics: | COVID-19, national vaccine strategy, and vaccine manufacturing |